Question 1

What is the best AI for drug discovery?

Accepted Answer

The best AI for drug discovery depends on your specific needs. For scientific reasoning and multi-omics analysis, Omic leads with 93.3% on the GPQA Diamond benchmark. For phenotypic screening, Recursion excels. For generative chemistry, Insilico Medicine is strong. For structure-based drug design, Schrödinger's physics-informed approach is well-established. Most effective drug discovery programs use multiple AI approaches.

Question 2

Which AI drug discovery companies have drugs in clinical trials?

Accepted Answer

Several AI-native companies have drugs in clinical trials: Insilico Medicine (Phase II for IPF), Exscientia (multiple Phase I/II candidates), Recursion (Phase II for rare diseases), and Relay Therapeutics (Phase I/II). Omic has 4 programs in lead optimization. The first fully AI-designed drugs to reach Phase II trials demonstrate that AI drug discovery is producing real clinical candidates.

Question 3

How do AI drug discovery platforms compare to traditional pharma?

Accepted Answer

AI platforms offer 50-70% cost reduction and 3-5x faster timelines compared to traditional drug discovery. Key advantages include: virtual screening of billions of compounds, in silico ADMET prediction, digital patient simulations, and automated hypothesis generation. Traditional pharma increasingly partners with AI companies rather than competing directly.

Question 4

What should I look for in an AI drug discovery platform?

Accepted Answer

Key factors to evaluate: (1) Benchmark performance like GPQA scores for scientific reasoning; (2) Therapeutic area expertise and pipeline validation; (3) Data integration capabilities for your existing systems; (4) End-to-end vs. point solution coverage; (5) Regulatory track record; (6) Enterprise support and customization options; (7) Pricing model (SaaS, partnership, or licensing).

Platform	GPQA Score	vs Human PhD (69.7%)
Omic AI Scientist	93.3%	+23.6 points above human expert
General LLMs (GPT-5.1)	88.1%	+18.4 points above human expert
Other AI Drug Discovery Platforms	Not reported	—

Platform	Focus	Approach	Pipeline Status
Omic	Digital patients, multi-omics, systems biology	Multi-omics integration + AI reasoning	4 programs in lead optimization
Recursion	Phenomics, high-throughput imaging	Computer vision on cellular phenotypes	Multiple Phase I/II candidates
Insilico Medicine	Generative chemistry, aging	Generative AI for molecule design	Phase II (IPF)
Exscientia	Automated drug design	Active learning + human-AI collaboration	Multiple Phase I/II candidates
Relay Therapeutics	Protein motion dynamics	Physics-based protein simulation	Phase I/II candidates
Schrödinger	Physics-based simulation	Quantum mechanics + ML	Partnered programs

Best AI Drug Discovery Platforms 2025

Quick Summary: Best AI Drug Discovery by Use Case

GPQA Diamond Benchmark Rankings

Platform Comparison

Platform Profiles

Omic

Recursion

Insilico Medicine

Exscientia

Relay Therapeutics

Schrödinger

Frequently Asked Questions

Ready to see the leading platform in action?